# Denovo Biopharma

Source: https://onco.cc/companies/denovo-biopharma/  
OnCo record `denovo-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Denovo is a San Diego biotech that revives failed drugs by finding the genetic marker of patients who did respond; it took enzastaurin back into phase 3 in lymphoma and glioblastoma with its DGM1 biomarker.

## Summary

Denovo Biopharma, based in San Diego, licenses drugs that failed in unselected populations and re-tests them in patients selected by germline biomarkers it discovers. Its lead programme, enzastaurin (DB102) with the DGM1 marker, was taken into the phase 3 ENGINE trial in diffuse large B-cell lymphoma and a phase 3 trial in glioblastoma, both registered on ClinicalTrials.gov under Denovo as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Denovo Biopharma LLC
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: https://denovobiopharma.com

## Sources

- Official website: https://denovobiopharma.com
- ClinicalTrials.gov: trials led by Denovo Biopharma LLC: https://clinicaltrials.gov/search?lead=Denovo%20Biopharma%20LLC
- Wikidata: https://www.wikidata.org/wiki/Q140046004

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/denovo-biopharma.json